Birabresib

Drug Profile

Birabresib

Alternative Names: MK 8628; OTX 015; Y-803

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Merck & Co; Mitsubishi Tanabe Pharma Corporation; OncoEthix
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Small molecules; Triazoles
  • Mechanism of Action BRD2-protein-inhibitors; BRD3 protein inhibitors; BRD4-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Phase I Haematological malignancies
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 23 May 2017 Merck terminates a phase I trial in Solid tumours (Late-stage disease) in USA, France, Switzerland, Canada, Spain and Belgium (PO) (NCT02698176)
  • 03 Mar 2017 Oncoethix completes a phase I trial in Solid tumours in France and Canada (PO) (NCT02259114)
  • 28 Dec 2016 OTX 015 is still in phase I trials for Haematological malignancies in France, Italy and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top